DM
CGEM icon

Deerfield Management’s Cullinan Oncology CGEM Stock Holding History

Deerfield Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-386,169
Closed -$5.49M – 83
2026
Q1 		$5.49M Hold
386,169
– – 0.06% 70
2025
Q4 		$4M Sell
386,169
-2,540,844
-87% -$22.9M 0.05% 71
2025
Q3 		$17.4M Sell
2,927,013
-928,539
-24% -$6.8M 0.27% 62
2025
Q2 		$29M Sell
3,855,552
-5,287
-0.1% -$42.5K 0.53% 37
2025
Q1 		$29.2M Buy
3,860,839
+481,440
+14% +$4.62M 0.58% 39
2024
Q4 		$41.2M Buy
3,379,399
+99,399
+3% +$1.43M 0.78% 32
2024
Q3 		$54.9M Sell
3,280,000
-237
-0% -$4.2K 0.82% 27
2024
Q2 		$57.2M Buy
3,280,237
+2,141,706
+188% +$45.6M 0.95% 27
2024
Q1 		$19.4M Buy
+1,138,531
New +$17.6M 0.34% 54
2022
Q2 		– Sell
-375,585
Closed -$3.93M – 128
2022
Q1 		$3.93M Sell
375,585
-296,105
-44% -$4M 0.09% 90
2021
Q4 		$10.4M Sell
671,690
-372,310
-36% -$7.43M 0.22% 83
2021
Q3 		$23.6M Hold
1,044,000
– – 0.46% 63
2021
Q2 		$26.9M Buy
+1,044,000
New +$32.1M 0.48% 69

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Deerfield Management's CGEM Position: Q2 2026 in Review

Deerfield Management sold out of Cullinan Oncology (CGEM) in Q2 2026, closing a stake of 386,169 shares — an estimated $5.49M sold.

Deerfield Management first reported a position in CGEM in Q2 2021 and held it in 13 quarters. The position peaked at $57.2M in Q2 2024. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Deerfield Management reported no remaining Cullinan Oncology position as of Q2 2026 after selling out during the quarter.
  • Deerfield Management sold 386,169 Cullinan Oncology shares in Q2 2026, an estimated $5.49M.
  • Deerfield Management first reported a position in Cullinan Oncology in Q2 2021 and held it in 13 quarters.
  • Deerfield Management's Cullinan Oncology position peaked at $57.2M in Q2 2024.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.